CD274 and neoplasm: Biomarkers predicting immunotherapy benefits have recently emerged, including those correlated with the inflammatory tumor microenvironment, such as PD-L1 protein expression in cancer and antigen-presenting cells, and markers demonstrating the increase of tumor-specific neoantigens like tumor mutational burden (TMB) (14, 15).